Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes - The CALM II study

被引:73
作者
Andersen, NH
Eiskjer, H
Poulsen, PL
Hansen, KW
Knudsen, ST
Helleberg, K
Poulsen, SH
Mogensen, CE
机构
[1] Aarhus Univ Hosp, Dept Internal Med Diabet & Endocrinol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Cardiol B, DK-8000 Aarhus C, Denmark
[3] Silkeborg Hosp, Dept Internal Med, Silkeborg, Denmark
[4] Viborg Hosp, Dept Internal Med, Viborg, Denmark
关键词
D O I
10.2337/diacare.28.2.273
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To assess and compare the long-term effects Of the combination of candesartan and lisinopril with high-dose lisinopril on systolic blood pressure in patients with hypertension and diabetes. RESEARCH DESIGN AND METHODS - This was a prospective, randomized, parallel-group, double-blind, double-dummy study with a 12-month follow-up. Drug therapy was either lisinopril 40 mg once daily or dual-blockade treatment with candesartan 16 mg once daily and lisinopril 20 mg once daily. The study, comprised 75 type I and type 2 diabetic patients aged 0 1 35-74 years. The main outcome measures were seated and 24-h ambulatory systolic blood pressure. RESULTS - Reduction in systolic blood pressure (24-h systolic blood pressure) reduction was obtained in both treatment arms (mean reduction at Final follow-up: dual blockade 6 mmHg vs. lisinopril 2 mmHg), but no significant difference was found between dual-blockade and 0 lisinopril 40 mg once daily (P = 0.10). Both treatments were generally well tolerated. and similar 0 0 1 low rates of side effects were found in the two groups. CONCLUSIONS - There was no statistically significant difference between lisinopril 40 mg once daily and lisinopril 20 mg in combination with candesartan 16 mg, once daily in reducing systolic blood pressure in hypertensive patients with diabetes. Diabetes Care 28:273-277. 2005.
引用
收藏
页码:273 / 277
页数:5
相关论文
共 24 条
[1]   Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus:: rationale and design [J].
Andersen, NH ;
Knudsen, ST ;
Poulsen, PL ;
Poulsen, SH ;
Helleberg, K ;
Eiskjær, H ;
Hansen, KW ;
Bek, T ;
Mogensen, CE .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2003, 4 (02) :96-99
[2]   ADDITIVE EFFECTS OF COMBINED ANGIOTENSIN-CONVERTING ENZYME-INHIBITION AND ANGIOTENSIN-II ANTAGONISM ON BLOOD-PRESSURE AND RENIN RELEASE IN SODIUM-DEPLETED NORMOTENSIVES [J].
AZIZI, M ;
CHATELLIER, G ;
GUYENE, TT ;
MURIETAGEOFFROY, D ;
MENARD, J .
CIRCULATION, 1995, 92 (04) :825-834
[3]   ACE-INHIBITOR MEDIATED REDUCTIONS IN RENAL SIZE AND MICROALBUMINURIA IN NORMOTENSIVE, DIABETIC SUBJECTS [J].
BAKRIS, GL ;
SLATAPER, R ;
VICKNAIR, N ;
SADLER, R .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1994, 8 (01) :2-6
[4]  
BARCELLS E, 1997, AM J PHYSIOL, V273, pH1769
[5]   Improving the quality of reporting of randomized controlled trials - The CONSORT statement [J].
Begg, C ;
Cho, M ;
Eastwood, S ;
Horton, R ;
Moher, D ;
Olkin, I ;
Pitkin, R ;
Rennie, D ;
Schulz, KF ;
Simel, D ;
Stroup, DF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (08) :637-639
[6]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[7]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[8]   The influence of dose of angiotensin I-converting enzyme inhibitor on systolic blood pressure variability in heart failure: a substudy of the Assessment of Treatment with Lisinopril and Survival in Heart Failure (ATLAS) trial [J].
Giles, TD ;
Kerut, EK ;
Roffidal, LE ;
Jones, R ;
Given, MB ;
Hutchinson, H ;
Tresznewsky, O .
BLOOD PRESSURE MONITORING, 2001, 6 (02) :81-84
[9]   AMBULATORY BLOOD-PRESSURE MEASUREMENT IN TYPE-2 DIABETIC-PATIENTS - METHODOLOGICAL ASPECTS [J].
HANSEN, KW ;
SCHMITZ, A ;
PEDERSEN, MM .
DIABETIC MEDICINE, 1991, 8 (06) :567-572
[10]   Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta [J].
Ihara, M ;
Urata, H ;
Kinoshita, A ;
Suzumiya, J ;
Sasaguri, M ;
Kikuchi, M ;
Ideishi, M ;
Arakawa, K .
HYPERTENSION, 1999, 33 (06) :1399-1405